Geron Corp
GERNHealthcare|Biotechnology|USA
$1.50
-0.07 (-4.15%)
Tangible Book
$0.36
Clinical Trials (24)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT04576156 A Study Comparing Imetelstat Versus Best Available Therapy for the Treatment of Intermediate-2 or High-risk Myelofibrosis (MF) Who Have Not Responded to Janus Kinase (JAK)-Inhibitor Treatment | Myelofibrosis | P3 | Active | 327 | RCT, Open-label | Imetelstat, Best Available Therapy (BAT) |
| NCT02598661 Study to Evaluate Imetelstat (GRN163L) in Participants With International Prognostic Scoring System (IPSS) Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) | Myelodysplastic Syndromes | P2P3 | Active | 289 | RCT, Double-blind | Imetelstat Sodium, Placebo |
| NCT05583552 Study to Evaluate Imetelstat in Patients With High-Risk MDS or AML Failing HMA-based Therapy | Myelodysplastic Syndromes, Acute Myeloid Leukemia | P2 | Active | 46 | Open-label | Imetelstat sodium |
| NCT05371964 A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination With Ruxolitinib in Participants With Myelofibrosis | Myelofibrosis | P1 | Recruiting | 36 | Open-label | Imetelstat sodium, Ruxolitinib |
| NCT06247787 A Study to Find the Highest Dose of Imetelstat in Combination With Fludarabine and Cytarabine for Patients With AML, MDS or JMML That Has Come Back or Does Not Respond to Therapy | Recurrent Childhood Acute Myeloid Leukemia, Recurrent Childhood Myelodysplastic Syndrome | P1 | Recruiting | 36 | Open-label | Cytarabine, Fludarabine, Hydrocortisone Sodium Succinate, Imetelstat, Leucovorin Calcium, Methotrexate |
| NCT07320235 Imetelstat Combinations in Relapsed AML | Relapsed Acute Myeloid Leukemia | P1 | Recruiting | 36 | Open-label | Imetelstat, Azacitidine, Venetoclax |
| NCT07436104 Mortality Control Program for Economically Productive Age Group in Tribal Area of Melghat. | Hypertension (HTN), Diarrhea | P4 | Completed | 72,564 | RCT, Double-blind | — |
| NCT02426086 Study to Evaluate Activity of 2 Dose Levels of Imetelstat in Participants With Intermediate-2 or High-Risk Myelofibrosis (MF) Previously Treated With Janus Kinase (JAK) Inhibitor | Myelofibrosis | P2 | Completed | 107 | RCT, Single-blind | Imetelstat 4.7 mg/kg, Imetelstat 9.4 mg/kg |
| NCT07549451 Phase 2 Study Of Imetelstat for Patient With Myelodysplastic/Myeloproliferative Neoplasms | Phase II, Imetelstat | P2 | Not Yet Recruiting | 30 | Open-label | Imetelstat |
| NCT01137968 Imetelstat as Maintenance Therapy After Initial Induction Chemotherapy in Non-small Cell Lung Cancer (NSCLC) | Non-small Cell Lung Cancer | P2 | Completed | 116 | RCT, Open-label | imetelstat, Bevacizumab |
| NCT01242930 Open Label Study With Imetelstat to Determine Effect of Imetelstat in Patients w/ Previously Treated Multiple Myeloma | Multiple Myeloma | P2 | Completed | 13 | Open-label | Imetelstat (7.5 mg/kg), lenalidomide standard of care, Imetelstat (9.4 mg/kg) |
| NCT01731951 Imetelstat Sodium in Treating Participants With Primary or Secondary Myelofibrosis | Primary Myelofibrosis, Secondary Myelofibrosis | P2 | Completed | 80 | RCT, Open-label | Imetelstat |
| NCT01243073 Open Label Study to Evaluate the Activity of Imetelstat in Patients With Essential Thrombocythemia or Polycythemia Vera | Essential Thrombocythemia, Polycythemia Vera | P2 | Completed | 20 | Open-label | Imetelstat |
| NCT01256762 Imetelstat in Combination With Paclitaxel (With or Without Bevacizumab) in Patients With Locally Recurrent or Metastatic Breast Cancer | Locally Recurrent or Metastatic Breast Cancer | P2 | Completed | 166 | RCT, Open-label | Imetelstat sodium, Bevacizumab, Paclitaxel |
| NCT01265927 A Study Inhibiting Telomerase to Reverse Trastuzumab Resistance in HER2+ Breast Cancer | Breast Neoplasms | P1 | Completed | 10 | Open-label | GRN163L in combination with trastuzumab |
| NCT00732056 A Study of GRN163L With Paclitaxel and Bevacizumab to Treat Patients With Locally Recurrent Or Metastatic Breast Cancer | Breast Cancer | P1 | Completed | 24 | Open-label | GRN163L |
| NCT00124189 Safety and Dose Study of GRN163L to Treat Patients With Chronic Lymphoproliferative Disease(CLD) | Chronic Lymphoproliferative Diseases | P1 | Completed | 48 | Open-label | GRN163L |
| NCT00310895 Safety and Dose Study of GRN163L Administered to Patients With Refractory or Relapsed Solid Tumor Malignancies | Solid Tumor Malignancies | P1 | Completed | 85 | Open-label | Imetelstat Sodium (GRN163L) |
| NCT01916187 Imetelstat Given Intravenously Alone and With Standard 13-Cis-Retinoic Acid in Children With Neuroblastoma | Neuroblastoma | P1 | Withdrawn | — | Open-label | Imetelstat |
| NCT00718601 Safety and Dose Study of GRN163L and Velcade to Treat Patients With Refractory or Relapsed Myeloma | Multiple Myeloma | P1 | Completed | 40 | Open-label | Imetelstat Sodium (GRN163L) |
| NCT00594126 Safety and Dose Study of GRN163L Administered to Treat Patients With Refractory or Relapsed Multiple Myeloma | Multiple Myeloma | P1 | Completed | 20 | Open-label | Imetelstat Sodium (GRN163L) |
| NCT00510445 Study of GRN163L With Paclitaxel and Carboplatin in Patients With Advanced or Metastatic Non Small Cell Lung Cancer | Lung Cancer | P1 | Completed | 27 | Open-label | Imetelstat Sodium (GRN163L) |
| NCT02473796 Home Based Child Care to Reduce Mortality and Malnutrition in Tribal Children of Melghat, India: CRCT | Acute Respiratory Tract Infections, Diarrhea | N/A | Completed | 7,594 | RCT, Open-label | — |
| NCT05937568 Expanded Access for Treatment With Imetelstat | Myelodysplastic Syndromes | APPROVED_FOR_MARKETING | — | — | Imetelstat |